HIPK2 and prostate cancer: Imberg-Kazdan et al [20] found that depletion of HIPK2 and MED19 in human prostate cancer cells decreased AR target gene expression and reduced the proliferation of androgen-dependent and castration-resistant prostate cancer cells.